It describes key biological processes that shape tumor heterogeneity and examines targeted therapies, including endocrine agents, HER2‐directed drugs, CDK4/6 and PI3K/AKT/mTOR inhibitors, antibody–drug conjugates, and immunotherapies, together with mechanisms of resistance and emerging treatment targets. Here, MTOR is linked to neoplasm.